LGALS1 and hepatocellular carcinoma: While the control (AAV9-treated) MASH-HCC mice had a mean L/B of 18%, the L/B of AAV9- lgals1 siRNA-treated mice was only 7.5%, not different from that of MAFLD mice (bar graph not shown).